Cellectis (CLLS) Retained Earnings (2014 - 2026)
Cellectis (CLLS) posted quarterly Retained Earnings of -$334.2 million for Q1 2026, down 1.4% year-over-year from -$338.9 million in Q1 2025, and down 25.38% quarter-over-quarter from -$266.5 million in Q4 2025.
Cellectis (CLLS) Retained Earnings (2014 - 2026) Analysis & Trends
Cellectis' Retained Earnings history runs 13 years deep, the most recent figure standing at -$334.2 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 1.4% year-over-year to -$334.2 million; the TTM figure through Mar 2026 stood at -$334.2 million (down 1.4% YoY), while the FY2025 annual figure was -$266.5 million, up 8.98% from the prior year.
- Retained Earnings for Q1 2026 stood at -$334.2 million, down from -$266.5 million in the prior quarter.
- The five-year high for Retained Earnings was -$266.5 million in Q4 2025, with the low at -$696.1 million in Q1 2022.
- The 5-year median for Retained Earnings is -$329.6 million (2025), against an average of -$353.5 million.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings surged 45.28% in 2022, then plunged 33.05% in 2024.
- Cellectis' Retained Earnings stood at -$333.4 million in 2022, then grew by 8.6% to -$304.7 million in 2023, then climbed by 3.89% to -$292.8 million in 2024, then grew by 8.98% to -$266.5 million in 2025, then declined by 25.38% to -$334.2 million in 2026.
- Business Quant data shows CLLS's Retained Earnings at -$334.2 million in Q1 2026, -$266.5 million in Q4 2025, and -$266.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | -334.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -334.17 Mn |
| Dec 31, 2025 | -266.54 Mn |
| Sep 30, 2025 | -266.59 Mn |
| Jun 30, 2025 | -266.59 Mn |
| Mar 31, 2025 | -329.56 Mn |
| Dec 31, 2024 | -292.85 Mn |
| Sep 30, 2024 | -405.80 Mn |
| Jun 30, 2024 | -405.73 Mn |
| Mar 31, 2024 | -405.81 Mn |
| Dec 31, 2023 | -304.71 Mn |
| Sep 30, 2023 | -304.99 Mn |
| Jun 30, 2023 | -305.39 Mn |
| Mar 31, 2023 | -439.22 Mn |
| Dec 31, 2022 | -333.37 Mn |
| Sep 30, 2022 | -330.60 Mn |
| Jun 30, 2022 | -320.81 Mn |
| Mar 31, 2022 | -696.06 Mn |
| Dec 31, 2021 | -584.13 Mn |
| Sep 30, 2021 | -586.72 Mn |
| Jun 30, 2021 | -586.28 Mn |